User login
Key clinical point: Elevated pretreatment plasma levels of programmed death-ligand 1 (PD-L1) predicted poor disease-specific survival (DSS) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC).
Major finding: The pretreatment PD-L1 levels were significantly lower in patients with metachronous vs synchronous metastases (P = .0412) and in those without vs with signs of disease progression (P = .0443), with a significant association observed between elevated PD-L1 levels and shorter DSS (P = .0257) and PFS (P = .0141).
Study details: Findings are from a retrospective analysis of 37 patients with stage IV mCRC who were included prior to any metastatic setting treatments.
Disclosures: This study was supported by the National Research, Development, and Innovation Office, Hungary. The authors declared no conflicts of interest.
Source: Dank M et al. Does elevated pre-treatment plasma PD-L1 level indicate an increased tumor burden and worse prognosis in metastatic colorectal cancer? J Clin Med. 2022;11(16):4815 (Aug 17). Doi: 10.3390/jcm11164815
Key clinical point: Elevated pretreatment plasma levels of programmed death-ligand 1 (PD-L1) predicted poor disease-specific survival (DSS) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC).
Major finding: The pretreatment PD-L1 levels were significantly lower in patients with metachronous vs synchronous metastases (P = .0412) and in those without vs with signs of disease progression (P = .0443), with a significant association observed between elevated PD-L1 levels and shorter DSS (P = .0257) and PFS (P = .0141).
Study details: Findings are from a retrospective analysis of 37 patients with stage IV mCRC who were included prior to any metastatic setting treatments.
Disclosures: This study was supported by the National Research, Development, and Innovation Office, Hungary. The authors declared no conflicts of interest.
Source: Dank M et al. Does elevated pre-treatment plasma PD-L1 level indicate an increased tumor burden and worse prognosis in metastatic colorectal cancer? J Clin Med. 2022;11(16):4815 (Aug 17). Doi: 10.3390/jcm11164815
Key clinical point: Elevated pretreatment plasma levels of programmed death-ligand 1 (PD-L1) predicted poor disease-specific survival (DSS) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC).
Major finding: The pretreatment PD-L1 levels were significantly lower in patients with metachronous vs synchronous metastases (P = .0412) and in those without vs with signs of disease progression (P = .0443), with a significant association observed between elevated PD-L1 levels and shorter DSS (P = .0257) and PFS (P = .0141).
Study details: Findings are from a retrospective analysis of 37 patients with stage IV mCRC who were included prior to any metastatic setting treatments.
Disclosures: This study was supported by the National Research, Development, and Innovation Office, Hungary. The authors declared no conflicts of interest.
Source: Dank M et al. Does elevated pre-treatment plasma PD-L1 level indicate an increased tumor burden and worse prognosis in metastatic colorectal cancer? J Clin Med. 2022;11(16):4815 (Aug 17). Doi: 10.3390/jcm11164815